Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer
一项针对转移性去势抵抗性前列腺癌的 I/II 期研究,评估了在研的 17,20-裂解酶抑制剂 orteronel (TAK-700) 与多西他赛-泼尼松联合用药的疗效。
期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-014-0199-x
Petrylak, Daniel P; Gandhi, Jitendra G; Clark, William R; Heath, Elisabeth; Lin, Jianqing; Oh, William K; Agus, David B; Carthon, Bradley; Moran, Susan; Kong, Ning; Suri, Ajit; Bargfrede, Michael; Liu, Glenn